WHAT ARE THE EFFECTS OF THIS DRUG?
↑ 4.18 pounds average over 52 weeks with dose of 4 mg per day when Rosiglitazone is given alone (27)
↑ 5.5 pounds in 26 weeks 8mg/d contrib by Rosiglitazone (Avandia) in combination with sulfonylurea (183)
↑ 0.79 lb average in 12 weeks with dose of 2 mg per day when Rosiglitazone given alone (181)
↑ 0.4 lb average in 12 weeks with dose of 1 mg per day when Rosiglitazone given alone (181)
↑ weight gain is fat and water for Rosiglitazone (25 and 27)
↑ 4.4 pounds in 4 months with both the 4 and 8 mg per day doses for Rosiglitazone when given alone (27)
↑ 6.38 pounds average over 52 weeks with dose of 8 mg per day when Rosiglitazone given alone (27)
↑ 5.72 pounds average over 52 weeks with dose of 8 mg per day when Rosiglitazone given alone (183)
↑ 6.82 pounds average over 26 weeks with dose of 8 mg per day when given Rosiglitazone alone (183)
↑ When Rosiglitazone is added to insulin weight gain more dramatic than expected for combination (27)
↑ 9.02 pounds average when 4mg/day Rosiglitazone is added to insulin in 6 months (183)
↑ 11.88 pounds in 26 weeks 8mg/d contrib by Rosiglitazone (Avandia) in combination insulin (183)
↑ In combo Rosiglitazone with sulfonylurea weight gain greater than expected for combination (27)
↑ 4.6 pounds average in 26 weeks 8mg/d contrib by Rosiglitazone (Avandia) in combination metformin (183)
↑ 9.9 pounds 26 weeks 8mg/day contribution by Rosiglitazone (Avandia) + sulfonylurea + metformin (183)
↑ 4.18 to 6.16 pounds in 1yr (27) for Rosiglitazone when given alone
↓ or Generally weight neutral and sometimes mild weight loss for metformin when given alone (672)
↓ Weight -2.42 pounds average vs placebo (no drug) time not specified in Meta-analysis study for metformin when given alone (700)
* FDA Alert: Thiazolidinediones, including Rosiglitazone, can cause or exacerbate congestive heart failure (CHF) in some patients.
Three other trials (mean duration, 46 months ; 14,067 total patients) comparing rosiglitazone with some other approved oral antidiabetic agents or placebo showed a statistically nonsignificant increased risk of MI and a statistically nonsignificant decreased risk of death. There have been no clinical trials directly comparing the cardiovascular risk of rosiglitazone and pioglitazone, another thiazolidinedione, but in a separate trial, pioglitazone (when compared with placebo) did not show an increased risk of MI or death.
Generic Name: Rosiglitazone &
Metformin